• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Venus Concept Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/15/25 7:15:23 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    false0001409269NASDAQ00014092692025-05-152025-05-15

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K


    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 15, 2025



    VENUS CONCEPT INC.
    (Exact name of registrant as specified in its charter)



    Delaware
    001-38238
    06-1681204
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification Number)
    235 Yorkland Blvd, Suite 900
    Toronto, Ontario M2J 4Y8
    (Address of principal executive offices, including Zip Code)

    Registrant’s telephone number, including area code: (877) 848-8430

    Not Applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, $0.0001 par value per share
      VERO   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02.
    Results of Operations and Financial Condition.

    On May 15, 2025, Venus Concept Inc. issued a press release relating to its financial results for the three months ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01.
    Financial Statements and Exhibits.

    Exhibit
     
    No.
    Description
       
    99.1
    Pres release dated May 15, 2025
       
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
       


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    VENUS CONCEPT INC.
         
    Date: May 15, 2025
    By:
    /s/ Domenic Della Penna
       
    Domenic Della Penna
       
    Chief Financial Officer



    Get the next $VERO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Venus Concept Announces First Quarter 2025 Financial Results

      TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2025. Summary of Financial Results & Recent Progress: Total revenue for the first quarter of $13.6 million, down 22% year-over-year, reflecting continued difficult market conditions. First quarter operating expenses declined 6% year-over-yearFirst quarter GAAP net loss of $12.4 million, compared to $9.8 million last yearFirst quarter Adjusted EBITDA loss of $8.3 million, compared to $5.1 million last year On April 1, 2025, the Company exchanged $11.0 million of its sub

      5/15/25 7:00:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock

      TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were approximately $1.57 million, before deducting placement agent fees and other offering expenses payable by the Company. The total gross proceeds from the offering and the previous

      4/14/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

      TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 14, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approx

      4/11/25 8:02:39 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Venus Concept Inc.

      10-Q - Venus Concept Inc. (0001409269) (Filer)

      5/15/25 7:21:08 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      5/15/25 7:15:23 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      5/2/25 4:15:20 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    See more
    • Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

      TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

      10/12/23 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

      TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

      10/11/22 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Ross J. Portaro as President of Global Sales

      TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

      10/12/21 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/8/24 7:51:38 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/3/24 7:59:41 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

      SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

      9/30/24 9:53:26 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Financials

    Live finance-specific insights

    See more
    • Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

      TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

      4/7/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 financial results will be released before the market opens on Monday, March 31, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on March 31, 2025 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13751985. A live webcast of the call will also be provided on the investor relations section of the

      3/3/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024

      TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's

      10/2/24 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Madryn Asset Management, Lp

      4 - Venus Concept Inc. (0001409269) (Issuer)

      4/2/25 5:47:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Director Natale Anthony sold $13,194 worth of shares (42,768 units at $0.31) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      12/4/24 5:43:14 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Large owner Masters Michael Willingham sold $179,641 worth of shares (306,135 units at $0.59) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      10/2/24 7:54:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care